UK markets closed

Adverum Biotechnologies, Inc. (0HA3.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
1.7020+0.0200 (+1.19%)
At close: 05:18PM BST

Adverum Biotechnologies, Inc.

100 Cardinal Way
Redwood City, CA 94063
United States
(650) 656-9323

Full-time employees123

Key executives

NameTitlePayExercisedYear born
Dr. Laurent FischerPres, CEO & Director977.23kN/A1964
Ms. Linda M. Rubinstein M.A.CFO, Principal Financial Officer & Principal Accounting Officer111.89kN/A1967
Mr. Kishor Peter Soparkar J.D.Chief Operating Officer656.96kN/A1971
Mr. John W. Rakow J.D.Sr. VP & Gen. Counsel954.24kN/A1957
Dr. Setareh Seyedkazemi Pharm.D.Chief Devel. Officer834.57kN/A1974
Dr. R. Andrew Ramelmeier Ph.D.Chief Technology OfficerN/AN/A1962
Dr. Brigit Riley Ph.D.Chief Scientific OfficerN/AN/A1978
Ms. Dena HouseSr. VP of HR, Organizational Devel. & LearningN/AN/AN/A
Ms. Carla FiankanSr. VP of Regulatory AffairsN/AN/AN/A
Dr. Jim Wang Ph.D.Chief Regulatory OfficerN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Corporate governance

Adverum Biotechnologies, Inc.’s ISS governance QualityScore as of 1 September 2023 is 7. The pillar scores are Audit: 5; Board: 5; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.